Biotie Therapies - Company Announcement

Biotie's loan obligations to Tekes reduced by EUR 2.2 million

BIOTIE THERAPIES CORP.      STOCK EXCHANGE RELEASE            28 November 2011,
at 9.00 a.m.

Biotie's loan obligations to Tekes reduced by EUR 2.2 million

The Finnish Funding Agency for Technology and Innovation (Tekes) has, based on
an application from Biotie, informed the company that it has decided to forgive
certain capital loans relating to Biotie's  bioheparin project discontinued in
2006. Biotie's justification for the application was that the Tekes funded R&D
project did not lead to commercially profitable business.

The loan forgiveness will reduce the group's non-current financial liabilities
on the consolidated statement of financial position by EUR 2.2 million and
increase financial income on the consolidated statement of comprehensive income
by EUR 2.2 million in the full year financial statements for 2011. In addition,
all accrued interest relating to these loans are also forgiven. This will reduce
other non-current liabilities on the consolidated statement of financial
position by EUR 0.4 million and increase financial income on the consolidated
statement of comprehensive income by EUR 0.4 million in the full year financial
statements for 2011.

As at 31 December 2010 the Company's loan obligations to Tekes were EUR 19.7
million as capital loans and EUR 4.2 million as R&D loans.

In Turku, 28 November 2011

Biotie Therapies Corp.
Timo Veromaa, President and CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail:virve.nurmi@biotie.com
www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media


[HUG#1566927]